Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 2;11(1):33.
doi: 10.1186/s13045-018-0564-x.

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology

Lanping Xu  1 , Hu Chen  2 , Jing Chen  3 , Mingzhe Han  4 , He Huang  5 , Yongrong Lai  6 , Daihong Liu  7 , Qifa Liu  8 , Ting Liu  9 , Ming Jiang  10 , Hanyun Ren  11 , Yongping Song  12 , Zimin Sun  13 , Jianmin Wang  14 , Depei Wu  15 , Daobin Zhou  16 , Ping Zou  17 , Kaiyan Liu  1 , Xiaojun Huang  18   19
Affiliations
Review

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology

Lanping Xu et al. J Hematol Oncol. .

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat malignant hematological neoplasms and non-malignant hematological disorders. Approximately, 5000 allo-HSCT procedures are performed in China annually. Substantial progress has been made in haploidentical HSCT (HID-HSCT), pre-transplantation risk stratification, and donor selection in allo-HSCT, especially after the establishment of the "Beijing Protocol" HID-HSCT system. Transplant indications for selected subgroups in low-risk leukemia or severe aplastic anemia (SAA) differ from those in the Western world. These unique systems developed by Chinese doctors may inspire the refining of global clinical practice. We reviewed the efficacy of allo-HSCT practice from available Chinese studies on behalf of the HSCT workgroup of the Chinese Society of Hematology, Chinese Medical Association and compared these studies to the consensus or guideline outside China. We summarized the consensus on routine practices of all-HSCT in China and focused on the recommendations of indications, conditioning regimen, and donor selection.

Keywords: Allogeneic hematopoietic transplantation; China; Conditioning regimen; Consensus; Donor selection; Indication; Standard of care.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Donor research flowchart for allo-HSCT
See this image and copyright information in PMC

References

    1. Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, Bouzas LF, Confer D, Greinix H, Horowitz M, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the worldwide network for blood and marrow transplantation group including the global survey. Bone Marrow Transplant. 2016;51:778–785. doi: 10.1038/bmt.2016.18. - DOI - PMC - PubMed
    1. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, Gratwohl M, Bouzas LF, Confer D, Frauendorfer K, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2:e91–100. doi: 10.1016/S2352-3026(15)00028-9. - DOI - PubMed
    1. Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, Gennery A, Kroger N, Kuball J, Lanza F, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52:811–817. doi: 10.1038/bmt.2017.34. - DOI - PMC - PubMed
    1. Lv M, Huang X. Fighting against hematological malignancy in China: from unique system to global impact. Sci China Life Sci. 2015;58:1183–1190. doi: 10.1007/s11427-015-4926-0. - DOI - PubMed
    1. Xu LP, Wu DP, Han MZ, Huang H, Liu QF, Liu DH, Sun ZM, Xia LH, Chen J, Wang HX, et al. A review of hematopoietic cell transplantation in China: data and trends during 2008-2016. Bone Marrow Transplant. 2017;52:1512–1518. doi: 10.1038/bmt.2017.59. - DOI - PubMed

Publication types

MeSH terms